A Randomized, Double-Blind, Multicenter, Parallel-group, Phase 2 Study to Evaluate the Efficacy and Safety of Subcutaneous TAK-361S, 3 dosage levels in the Prevention of Diphtheria, Pertussis, Tetanus, and Poliomyelitis in Healthy Pediatric Subjects

Trial Profile

A Randomized, Double-Blind, Multicenter, Parallel-group, Phase 2 Study to Evaluate the Efficacy and Safety of Subcutaneous TAK-361S, 3 dosage levels in the Prevention of Diphtheria, Pertussis, Tetanus, and Poliomyelitis in Healthy Pediatric Subjects

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs TAK 361S (Primary)
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 02 Feb 2015 Status changed from recruiting to discontinued, according to a Takeda media release.
    • 02 Feb 2015 Takeda has voluntary discontinued the development of TAK-361S, according to a media release.
    • 19 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top